KR830001945A - β-락탐을 함유하는 항박테리아제 및 β-락타메이즈 억제물질의 제조방법 - Google Patents
β-락탐을 함유하는 항박테리아제 및 β-락타메이즈 억제물질의 제조방법 Download PDFInfo
- Publication number
- KR830001945A KR830001945A KR1019800000767A KR800000767A KR830001945A KR 830001945 A KR830001945 A KR 830001945A KR 1019800000767 A KR1019800000767 A KR 1019800000767A KR 800000767 A KR800000767 A KR 800000767A KR 830001945 A KR830001945 A KR 830001945A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- structural formula
- structural
- lower alkyl
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 239000003781 beta lactamase inhibitor Substances 0.000 title 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003952 β-lactams Chemical class 0.000 title 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 7
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims 6
- USVZHTBPMMSRHY-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-chlorophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Cl USVZHTBPMMSRHY-UHFFFAOYSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 150000000475 acetylene derivatives Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 1
- CJZSHVMLIFESHD-UHFFFAOYSA-O (3-amino-4-oxo-1-sulfanylpyridin-2-yl)oxycarbonylazanium Chemical compound NC(=O)OC1=C(N)C(O)=CC=[N+]1S CJZSHVMLIFESHD-UHFFFAOYSA-O 0.000 claims 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical group [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/568—Four-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (3)
- 다음 구조식(2)의 화합물을 구조식 X'C≡CY와 반응시켜서 다음 구조식(3)의 화합물을 얻고 이를 염기 조건하에서 이성화시켜서 다음 구조식(4)의 화합물을 얻으며, X'를 X(=CH2Z)로 치환반응에 의해 전환시킬 수 있으며, 구조식(4)의 화합물을 환원, 오존화 및 가수분해 시켜서 다음 구조식(14)의 화합물을 얻고 이를 구조식 CHOCOOR인 글리옥실산의 적당한 에스테르와 반응시켜서 다음 구조식(15)의 화합물을 얻고 이를 다음 구조식(16)의 클로로 유도체로 전환시키며, 구조식(16)의 화합물을 다음 구조식(11)의 포스포란으로 변환시키고 이를 폐환시켜서 다음 구조식(1)의 화합물을 제조하는 방법.상기 구조식에서,R은 수소원자, 저급알킬, 2, 2, 2-트리클로로에틸, 아세토닐, 벤질, P-니트로벤질, P-메톡시벤질, 페닐, P-니트로페닐, 벤질히드릴 또는 생체 내 대사활성화를 거쳐 유리한 약동학적 성질을 가지는 것으로 알려진 잔기 등이며,R'은 수소원자, 저급알킬, 저급알콕시, 사이클로알킬 또는 하이드록시알킬(하이드록시알킬의 알콜성 작용기는 유리 또는 보호된다)이고,Z는 수소 또는 할로겐원자, 하이드록시, 아미노, 카바모일옥시, 멀캅토, 피리디늄 또는 구조식 OR2, OCOR2, NHCOR2및 SR3(이 때 R2및 R3는 각각 저급알킬, 아릴 또는 헤테로사이클환을 나타내며 각각은 치환되거나 비치환일 수 있다)를 나타내고,R5는 알킬기를 나타내며,Ph는 페닐이다.X'C≡CY에서X'는 CH2Z'이며, 이 때 Z'는 할로겐 또는 수소원자 하이드록시, 아미노, 카바모일옥시 또는 구조식 OR2, OCOR2, NHCOR2이고 여기서 C2는 저급알킬, 아릴 또는 헤테로사이클환을 나타내며,Y는 수소원자, 저급알킬, 시아노 또는 구조식 COOR5거나 CH2Z'이다(이 때 R5는 저급알킬이다).
- 구조식(2)의 화합물을 구조식 X'C≡CY의 아세틸렌 유도체와 반응시켜서 구조식(3)의 화합물을 얻고 이를 염기성 조건하에서 이성화시켜서 구조식(4)의 화합물을 얻으며, X'를 치환반응에 의해서 구조식 CH2Z인 X로 전환시킬 수 있으며 구조식(4)의 화합물을 선택적으로 오존화시켜서 n=1인 다음 구조식(5)의 화합물을 얻고 이를 환원시켜 n=0인 구조식(5)의 화합물을 얻으며 다시 가수분해해서 다음 구조식(6)의 화합물을 얻고 이 (6)의 화합물을 구조식 CHOCOOR인 글리옥실산의 적당한 에스테르와 반응시켜 다음 구조식(7)의 화합물을 얻으며 이를 다음 구조식(8)의 클로로 유도체로 전환시키고 다시 다음 구조식(9)의 포스포란으로 변환시키며 이를 오존화시켜 구조식(11)의 화합물을 얻고 이 구조식(11)의 화합물을 폐환시켜서 구조식(1)의 화합물을 제조하는 방법.상기 구조식에서,각 기는 특허청구범위 1에서 설명된 바와 같다.
- 구조식(2)의 화합물을 구조식 X'C CY의 아세틸렌 유도체와 반응시켜서 구조식(3)의 화합물을 얻고 이들 염기성 조건하에서 이성화시켜서 구조식(4)의 화합물을 얻으며, X'를 치환 반응에 의해 X(CH2Z)로 전환시킬 수 있으며 구조식(4)의 화합물을 선택적으로 오존화 해서 구조식(5)의 화합물을 얻고 이를 가수분해해서 구조식(6)의 화합물을 얻으며 이것을 구조식 CHOCOOR인 글리옥실산의 적당한 에스테르와 반응시켜서 구조식(7)의 화합물을 얻고 이를 구조식(8)의 클로로 유도체로 전환시키며 이를 다시 구조식(9)의 화합물로 변환시키고 이 화합물을 환원시켜 다음 구조식(10)의 화합물을 얻고 (10)의 화합물을 오존화하여 구조식(11)의 화합물을 얻으며 이를 폐환시켜 구조식(1)의 화합물을 제조하는 방법.상기 구조식에서,기 설명은 전술한 바와 같다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB7906634 | 1979-02-24 | ||
GB7906634 | 1979-02-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR830001945A true KR830001945A (ko) | 1983-05-19 |
KR840000865B1 KR840000865B1 (ko) | 1984-06-20 |
Family
ID=10503424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019800000767A KR840000865B1 (ko) | 1979-02-24 | 1980-02-25 | β-락탐-함유 항균제의 제조방법 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPS55136288A (ko) |
KR (1) | KR840000865B1 (ko) |
BE (1) | BE881862A (ko) |
ZA (1) | ZA80993B (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5625110A (en) * | 1978-12-18 | 1981-03-10 | Bristol Myers Co | Antibacterial |
NO831160L (no) * | 1982-04-08 | 1983-10-10 | Erba Farmitalia | Fremstilling av substituerte penem-derivater |
GB8300295D0 (en) * | 1983-01-06 | 1983-02-09 | Erba Farmitalia | Penem esters |
GB8416651D0 (en) * | 1984-06-29 | 1984-08-01 | Erba Farmitalia | Penem derivatives |
EP0937725A3 (en) | 1992-04-28 | 2004-12-01 | Tanabe Seiyaku Co., Ltd. | Method for removing the protecting group for hydroxy group |
DE69805975T2 (de) | 1997-12-29 | 2002-12-19 | Res Corp Technologies Inc | 2-beta-substituierte-6-alkylidenpenizillansäure-derivate als beta-laktamase inhibitoren |
US6407091B1 (en) | 1999-04-15 | 2002-06-18 | Research Corporation Technologies, Inc. | β-lactamase inhibiting compounds |
JP2005502687A (ja) | 2001-07-24 | 2005-01-27 | アラムクス エルエルシー | β−ラクタマーゼ阻害剤としての7−アルキリデン−3−置換型−3−セフェム−4−カルボキシラート |
JP2005525399A (ja) | 2002-04-04 | 2005-08-25 | アラムクス エルエルシー | セリンおよびメタロ−β−ラクタマーゼの阻害剤 |
-
1980
- 1980-02-21 ZA ZA00800993A patent/ZA80993B/xx unknown
- 1980-02-22 BE BE0/199502A patent/BE881862A/fr not_active IP Right Cessation
- 1980-02-23 JP JP2108080A patent/JPS55136288A/ja active Granted
- 1980-02-25 KR KR1019800000767A patent/KR840000865B1/ko active
Also Published As
Publication number | Publication date |
---|---|
KR840000865B1 (ko) | 1984-06-20 |
ZA80993B (en) | 1981-02-25 |
JPS55136288A (en) | 1980-10-23 |
JPH03396B2 (ko) | 1991-01-07 |
BE881862A (fr) | 1980-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT80942A (fr) | Procede de preparation de nouveaux derives du pyrrole | |
KR830001945A (ko) | β-락탐을 함유하는 항박테리아제 및 β-락타메이즈 억제물질의 제조방법 | |
ES430117A1 (es) | Un procedimiento mejorado para la preparacion de hetacefa- lexina. | |
JPS5517386A (en) | Novel oxadiazolopyrimidine derivative | |
ATE126230T1 (de) | Cephalosporinderivate und verfahren zur herstellung von cephem-verbindungen. | |
GB1314628A (en) | Method for preparing penicillin sulphoxides | |
ATE37542T1 (de) | Verfahren zur herstellung von n-(3,5dichlorphenyl)-oxazolidin-2,4-dionen. | |
GB1346744A (en) | Betalactam compounds and process for preparing same | |
GB1412856A (en) | Process for preparing desacetoxycephalosporins and intermediates | |
ES460338A1 (es) | Mejoras introducidas en un procedimiento para la preparacionde un beta-lactama-acido. | |
ES472821A1 (es) | Procedimiento para obtener acido 2-amino-2-fenilacetico op- ticamente activo, eventualmente sustituido | |
GB1439898A (en) | Method of preparing substituted cephalosporins and penicillins | |
ES8703401A1 (es) | Procedimiento para la obtencion de esteres del acido 4-aci- loxi-3-oxo-butirico | |
ES8304114A1 (es) | Procedimiento para preparar butirotiolactonas. | |
ES437842A1 (es) | Procedimiento para la preparacion de cefalosporinas. | |
US3868364A (en) | Improved process for producing penicillin compound | |
ES406344A1 (es) | Un procedimiento para la preparacion de acido 7-aminocefa- losporanico. | |
IL67148A0 (en) | Production of aminomethylphosphonic acid | |
KR840000118B1 (ko) | 옥사졸리노 아제티디논의 제조방법 | |
IE37949L (en) | Tetrazolylacetate esters and acids. | |
ATE2076T1 (de) | Verfahren zur herstellung von 5-(2,2,2- | |
GB1130370A (en) | Esters of 6-aminopenicillanic acid | |
KR790001872B1 (ko) | 세팔로스포린의 제조방법 | |
GB1312030A (en) | Penicillin compounds and a method of synthesising same | |
NO872006D0 (no) | Fremgangsmaate for fremstilling av cefalosporinderivater. |